Analyst Expectations For Arcellx's Future


During the last three months, 14 analysts shared their evaluations of Arcellx ACLX, revealing diverse outlooks from bullish to bearish.

The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 10 4 0 0 0
Last 30D 0 1 0 0 0
1M Ago 3 0 0 0 0
2M Ago 2 0 0 0 0
3M Ago 5 3 0 0 0

Insights from analysts' 12-month price targets are revealed, presenting an average target of $80.57, a high estimate of $87.00, and a low estimate of $72.00. Witnessing a positive shift, the current average has risen by 20.94% from the previous average price target of $66.62.

Breaking Down Analyst Ratings: A Detailed Examination

The analysis of recent analyst actions sheds light on the perception of Arcellx by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Cory Kasimov Evercore ISI Group Announces Outperform $85.00 -
Emily Bodnar HC Wainwright & Co. Lowers Buy $80.00 $82.00
Gil Blum Needham Maintains Buy $81.00 -
Gil Blum Needham Maintains Buy $81.00 -
Gil Blum Needham Maintains Buy $81.00 -
Gil Blum Needham Raises Buy $81.00 $72.00
Benjamin Burnett Stifel Maintains Buy $82.00 -
Judah Frommer Morgan Stanley Announces Overweight $81.00 -
Asthika Goonewardene Truist Securities Raises Buy $87.00 $57.00
Emily Bodnar HC Wainwright & Co. Raises Buy $82.00 $60.00
John Newman Canaccord Genuity Raises Buy $85.00 $66.00
Carter Gould Barclays Raises Overweight $73.00 $62.00
Gil Blum Needham Raises Buy $72.00 $71.00
Jack Allen Baird Raises Outperform $77.00 $63.00

Key Insights:

  • Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Arcellx. This information provides a snapshot of how analysts perceive the current state of the company.
  • Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Arcellx compared to the broader market.
  • Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Arcellx's stock. This comparison reveals trends in analysts' expectations over time.

Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Arcellx's market standing. Stay informed and make data-driven decisions with our Ratings Table.

Stay up to date on Arcellx analyst ratings.

Delving into Arcellx's Background

Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.

Arcellx: Delving into Financials

Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.

Revenue Growth: Arcellx's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 119.16%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.

Net Margin: Arcellx's net margin is impressive, surpassing industry averages. With a net margin of -18.34%, the company demonstrates strong profitability and effective cost management.

Return on Equity (ROE): Arcellx's ROE stands out, surpassing industry averages. With an impressive ROE of -1.47%, the company demonstrates effective use of equity capital and strong financial performance.

Return on Assets (ROA): Arcellx's ROA excels beyond industry benchmarks, reaching -0.9%. This signifies efficient management of assets and strong financial health.

Debt Management: Arcellx's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.18.

How Are Analyst Ratings Determined?

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.

Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.

Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs
Price Target
Posted In: Analyst RatingsBZI-AAR
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!